Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata

    February 2022 in “Rheumatology
    Dandan Chen, Wenhan Huang, Zhongjie Wang, Feifeng Ren, Lei Luo, Jun Zhou, Dongmei Huang, Ming Tian, Lin Tang
    Image of study
    TLDR Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
    The document presents a case study of a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis (DM) and alopecia areata. Initial treatment with prednisone, MMF, and tacrolimus for 2 months relieved some symptoms but did not stop hair loss. The addition of baricitinib, a selective JAK1/2 inhibitor, to the treatment regimen resulted in significant relief of the patient's rash, cessation of hair loss, and hair regrowth after 5 months. The document suggests that the overexpression of the JAK-STAT signalling pathway in both DM and alopecia areata may be a key factor in these conditions. This is the first reported case of using baricitinib to treat a patient with anti-MDA5 antibody-positive DM and alopecia areata, with significant results.
    View this study on academic.oup.com →

    Cited in this study

    Related